TABLE 3.
Serologic reactivity with commercial panels of anti-D
| Monoclonal anti-D |
Reactivity* |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clone | Isotype | epD† | DOL-1 ccDee | DOL-2 ccDee | DMI CcDee | DFW CcDee | DFL CcDee | DCS-1 ccDEe | DFR-1 CcDee | DFV ccDEe | Weak D type 4.0 ccDee |
| BS226‡ | IgM | 6.4 | ++ | ++++ | +++ | ++ | +++ | ++ | − | ++++ | +++ |
| BS232‡ | IgM | 6.4 | ++ | ND | +++ | ++ | +++ | ++ | − | ++++ | +++ |
| RUM-1‡ | IgM | 6.1 | +++ | ND | +++ | +++ | +++ | ++ | − | ++++ | ++++ |
| D175-2‡ | IgM | 6.1 | +++ | ND | ++++ | ++++ | +++ | +++ | + | ++++ | +++ |
| HM10§ | IgM | 6.6 | + | (+) | ++++ | ++ | + | + | − | ++++ | +++ |
| HM16§ | IgG | 6.4 | +++ | ++++ | ND | +++ | +++ | +++ | − | ++++ | +++ |
| P3X61§ | IgM | 6.1 | ++ | ++++ | +++ | +++ | +++ | + | − | ++++ | ++++ |
| P3X35§ | IgG | 5.4 | +++ | + | ND | − | + | +++ | − | ++++ | +++ |
| P3X212 11 F1§ | IgM | 8.2 | − | − | − | − | − | − | − | ++++ | ++ |
| P3X212 23 B10§ | IgM | 9.1 | ++ | ++++ | +++ | +++ | +++ | ++ | +++ | +++ | + |
| P3X241§ | IgG | 5.4 | +++ | ++++ | ND | +++ | +++ | +++ | ++ | +++ | +++ |
| P3X249§ | IgG | 2.1 | ++++ | ++++ | ND | +++ | ++++ | ++++ | ++++ | ++++ | ++++ |
| P3X290§ | IgG | 3.1 | +++ | ++ | ND | ++++ | +++ | ++++ | +++ | ++++ | +++ |
| LHM76/58‖ | IgG1λ | ND | ++++ | ND | ND | +++ | ++++ | +++ | +++ | ++++ | ++++ |
| LHM76/59‖ | IgG1 | ND | ++++ | ND | ND | +++ | ++++ | ++++ | +++ | ++++ | +++ |
| LHM174/102‖ | IgG3κ | 1.2 | − | ND | ND | +++ | +++ | + | − | +++ | +++ |
| LHM50/2B‖ | IgG1λ | 6.3 | ++++ | ND | ND | ++++ | +++ | ++++ | +++ | ++++ | ++++ |
| LHM169/81‖ | IgG3κ | 1.1 | ++++ | ND | ND | ++++ | +++ | +++ | +++ | ++++ | ++++ |
| ESD1‖ | IgG1κ | ND | ++++ | ND | ND | +++ | ++++ | ++++ | +++ | ++++ | ++++ |
| LHM76/55‖¶ | IgG1κ | 3.1 | +++ | ++++ | ND | +++ | +++ | +++ | +++ | +++ | ++++ |
| LHM77/64‖¶ | IgG1κ | 9.1 | ++++ | ++++ | ND | ++++ | +++ | ++++ | ++++ | ++++ | ++++ |
| LHM70/45‖¶ | IgG1λ | 1.2 | − | − | ND | +++ | +++ | + | − | +++ | +++ |
| LHM59/19‖¶ | IgG3κ | 8.1 | − | − | ND | (+) | +++ | + | + | ++++ | +++ |
| LHM169/80‖¶ | IgG3λ | 6.3 | +++ | ++++ | ND | +++ | +++ | +++ | +++ | +++ | +++ |
| LHM57/17‖ | IgG1λ | 6.3 | ++ | ND | − | − | − | + | − | ++++ | +++ |
| LDM-1¶ | IgM | ND | +++ | ++++ | +++ | +++ | +++ | +++ | (+) | +++ | +++ |
| BS221** | IgG | 6.3 | +++ | ND | ND | +++ | +++ | ++++ | ++++ | +++ | +++ |
| BS227** | IgG | 2.2 | +++ | ND | ND | +++ | ++++ | ++ | − | +++ | +++ |
| BS228** | IgG | 6.3 | ++++ | ND | ND | +++ | ++++ | ++++ | ++++ | ++++ | +++ |
| BS229** | IgG | 5.4 | ++++ | ND | ND | ++++ | +++ | +++ | − | ++++ | ++++ |
| BS231** | IgG | 5.4 | ++++ | ND | ND | +++ | ++ | ++++ | − | +++ | ++++ |
| H41** | IgG | 3.1 | +++ | ND | ND | ++++ | ++++ | +++ | ++++ | ++++ | +++ |
Tests were performed in gel matrix test with antiglobulin if not stated otherwise. DOL-2 testing was done in tube, except for the six monoclonal anti-D from DiaMed.
epD patterns as described previously by Scott.24
Monoclonal anti-D approved for routine use in Germany (BS226 and BS232, Seraclone anti-D (RH1), Biotest; RUM-1, immuClone anti-D rapid and D175-2, immuClone anti-D fast, Immucor).
D-Screen, Diagast, Loos, France.
Advanced partial RhD typing kit, Alba Bioscience, Edinburgh, UK. The results obtained with LHM76/58 and with the monoclonal antibody Number 74, documented as LHM76/58, in the Nantes workshop24 differed.
ID-Partial RhD-Typing Set, DiaMed.
Monoclonal anti-D panel, Biotest.
ND = not determined.